- Home
- TXT vs SNY Comparison
TXT vs SNY Comparison
Compare TXT & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXT
- SNY
- Stock Information
- Founded
- TXT 1923
- SNY 1994
- Country
- TXT United States
- SNY France
- Employees
- TXT N/A
- SNY N/A
- Industry
- TXT Aerospace
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- TXT Industrials
- SNY Health Care
- Exchange
- TXT Nasdaq
- SNY Nasdaq
- Market Cap
- TXT N/A
- SNY 123.6B
- IPO Year
- TXT N/A
- SNY N/A
- Fundamental
- Price
- TXT $68.42
- SNY $53.63
- Analyst Decision
- TXT Hold
- SNY Buy
- Analyst Count
- TXT 9
- SNY 2
- Target Price
- TXT $89.11
- SNY $62.50
- AVG Volume (30 Days)
- TXT 1.7M
- SNY 3.6M
- Earning Date
- TXT 04-24-2025
- SNY 04-24-2025
- Dividend Yield
- TXT 0.12%
- SNY 3.08%
- EPS Growth
- TXT N/A
- SNY 39.56
- EPS
- TXT 4.44
- SNY 5.45
- Revenue
- TXT $13,873,000,000.00
- SNY $48,817,552,946.00
- Revenue This Year
- TXT $7.85
- SNY $5.35
- Revenue Next Year
- TXT $4.52
- SNY $6.69
- P/E Ratio
- TXT $15.44
- SNY $9.60
- Revenue Growth
- TXT 0.57
- SNY N/A
- 52 Week Low
- TXT $57.70
- SNY $45.80
- 52 Week High
- TXT $94.57
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- TXT 51.09
- SNY 50.20
- Support Level
- TXT $64.05
- SNY $50.46
- Resistance Level
- TXT $66.83
- SNY $51.64
- Average True Range (ATR)
- TXT 2.84
- SNY 1.60
- MACD
- TXT 0.56
- SNY 0.15
- Stochastic Oscillator
- TXT 97.99
- SNY 65.92
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.